This observation was not confirmed by our (Bettuzzi et al, 2000; Scaltriti et al, 2004; Caporali et al, 2004) and other publications (Stuart et al, 2004), demonstrating that clusterin is indeed more frequently downregulated in prostate cancer. This evidence concerns the gene CLU and prostate carcinoma.